Stroke, Vol 15, 271-275, Copyright © 1984 by American Heart Association
G D'Andrea, M Toldo, A Cananzi and F Ferro-Milone
Although platelet activation is known to occur during migraine attacks, the
cause-effect relationship remains to be determined. This problem was
approached by studying the possible occurrence of platelet activation in
vivo in headache-free periods of subjects affected by common or classic
migraine and, subsequently, by verifying the possibility of its
pharmacological control through administration of a classic
anti-aggregation drug such as aspirin (ASA). The plasma levels of
beta-thromboglobulin (beta-TG) and platelet factor 4 (PF4), indices of the
occurrence of platelet activation in vivo, were therefore first assayed in
both groups of migraine sufferers in the absence of therapy and then during
the administration of aspirin (50 mg/daily). In the group of 15 patients
affected by classic migraine, basal plasma levels of beta-TG and PF4 were
significantly higher than control subjects. On the other hand, only beta-TG
plasma levels were significantly higher in the group of 18 patients
affected by common migraine. Patients suffering from classic migraine
showed a high incidence of platelet activation (greater than 90%) in
comparison with common migraine patients (approximately 33%). This suggests
that platelet activation occurs in vivo in migrainous patients also during
headache-free periods. Administration of aspirin to the patients affected
by common and classic migraine caused a decrease in plasma beta-TG and PF4
concentration. Consequently, pharmacological treatment with aspirin in
adequate dose may prove to be helpful in diminishing the vascular side-
effects known to occur in migraine sufferers.
ARTICLES
Study of platelet activation in migraine: control by low doses of aspirin
|
Stroke Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 1984 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |